Recent Finacing
Recent Raise
Acepodia develops off-the-shelf allogeneic NK and gamma-delta T cell therapies that use Antibody-Cell Conjugation to link tumor-targeting antibodies to an oNK cell line, advancing ACE1702 in Phase 1.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
